

ITL Achieves Record Month

ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months.

ITL Healthcare saw an increase in sales of its IV Starter Kit and ITL BioMedical began initial supply of products under the global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext: BIM), a multinational biotechnology company, as announced in October 2016.

In February ITL announced profit after tax of \$2.1m for the 6 months to 31st December, up 104% from the corresponding 2015 period and revenues of \$17.5m, up 11%. The Board stated it expects “a strong result for the full financial year even allowing for some seasonality in the 2nd half year”.

Bill Mobbs, ITL Executive Chairman commented; “this is the culmination of a lot of hard work across ITL Health Group. Whilst February sales included some initial stocking up, we are confident that this is the first step in the anticipated growth of SSK product sales in the future.”

Bill Mobbs
Executive Chairman

About ITL Health Group (ITL) www.ITLHealthGroup.com

ITL Health Group is an innovative global medical technology company that creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the blood culture testing market, estimated to be worth US\$3.3bn.

ITL maintains four divisions including ITL BioMedical, ITL Healthcare, ITL Clinical and MyHealthTest. The Company holds an IP portfolio of 48 patents and sells into 55 countries, protecting healthcare workers in millions of procedures annually.

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange
Code: ITD

Ordinary Shares
95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au